The abstract is read at the publisher; the summary is JClub's.
In the 2R2 trial of rifampicin-based tuberculosis preventive therapy, a two-fold higher rifampicin AUC0-24 predicted increased odds of protocol-defined adverse events leading to permanent discontinuation (aOR 1.88).
- Why it matters: Rifampicin TPT may shorten treatment, but large pharmacokinetic variability can produce different safety and tolerability outcomes at the same dose.
- What they did: Using a population pharmacokinetic model built from 440 participants, the study predicted rifampicin exposure for 1,368 adults and adolescents, imputing missing exposure metrics via 1,000 simulated datasets and fitting multivariable logistic regression across imputations.
- The result: Higher AUC0-24 and Cmax were linked to higher odds of discontinuation and tolerability symptoms, with similar exposure patterns for rash/allergy/hypersensitivity and gastrointestinal intolerance, but no significant hepatotoxicity association; exposure-based models discriminated slightly better than dose-based models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.